AI Article Synopsis
- A 26-week carcinogenicity study was conducted on ampicillin (ABPC) using Tg-rasH2 mice as part of the ILSI-HESI ACT program.
- ABPC was administered at varying doses (0, 350, 1000, 3000 mg/kg) to Tg-rasH2 mice and (0, 3000 mg/kg) to Non-Tg mice, while a positive control (MNU) was given to evaluate tumor development.
- The results indicated no increase in tumor development in Tg-rasH2 mice, suggesting that ampicillin does not exhibit carcinogenic properties in this study.
Article Abstract
As a part of the ILSI-HESI Alternative to Carcinogenicity Testing (ACT) program, we performed a 26-week carcinogenetic study of nonmutagenic drug, ampicillin (ABPC) in Tg-rasH2 mice. ABPC was given to Tg-rasH2 mice (0, 350, 1000, 3000 mg/kg, p.o.) and Non-Tg mice (0, 3000 mg/kg, p.o.) daily for 26 weeks. As a positive control, a single dose of MNU was administered once to Tg-rasH2 mice (75 mg/kg, i.p.). In this study, Tg-rasH2 mice did not demonstrate any increases in tumor development in response to ABPC. Thus, ABPC had no carcinogenicity in the 26-week carcinogenesis study in Tg-rasH2 mice or in a 2-year carcinogenesis study in B6C3F1 mice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2131/jts.27.147 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!